A PHASE IB-II STUDY OF HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE BORTEZOMIB AND ABATACEPT FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Graft-versus-host Disease (gvhd)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients with hematological malignancies undergoing an allogeneic transplant with a fludarabine and busulfan (myeloablative or reduced intensity conditioning regimen) or fludarabine, busulfan and thiotepa myeloablative conditioning regimen, and HLA matched sibling or =7 out of 8 allele level HLA matched unrelated donor (high resolution match at loci A, B, C, and DRB1) transplant.
    2. Karnofsky score greater than or equal to 70%.
    3. No evidence of progressive bacterial, viral, or fungal infection.
    4. Creatinine clearance >50 mL/min/1.72m2.

You may not be eligible for this study if the following are true:

    1. Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure.
    2. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
    3. Diagnosed or treated for another malignancy within 3 years of enrollment.
    4. Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.